34680-81-4

Basic information

• Product Name: 2-BROMO-N-METHYLACETAMIDE
• Synonyms: 2-BROMO-N-METHYLACETAMIDE;CHEMBRDG-BB 4023689;acetamide, 2-bromo-N-methyl-;2-bromo-N-methylacetamide(SALTDATA: FREE);2-bromo-N-methyl-ethanamide
• CAS NO: 34680-81-4
• Molecular Formula: C₃H₆BrNO
• Molecular Weight: 151.99
• Mol File: 34680-81-4.mol
• Article Data: 21

Chemical Properties

• Boiling Point: 273.6 °C at 760 mmHg
• Flash Point: 119.3 °C
• Appearance: /
• Density: 1.564 g/cm³
• Vapor Pressure: 0.00568mmHg at 25°C
• Refractive Index: 1.473
• PKA: 14.01±0.46(Predicted)
• CAS DataBase Reference: 2-BROMO-N-METHYLACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMO-N-METHYLACETAMIDE(34680-81-4)
• EPA Substance Registry System: 2-BROMO-N-METHYLACETAMIDE(34680-81-4)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 34680-81-4(Hazardous Substances Data)

Usage

General Description

2-Bromo-N-methylacetamide is an organic chemical compound with the molecular formula C3H6BrNO. It is a white to off-white crystalline powder that is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. This chemical is also used as an intermediate in the manufacturing of other organic compounds, such as dyes and polymers. It is important to handle this chemical with care and use appropriate safety measures, as it can be harmful if ingested, inhaled, or in contact with skin. Additionally, it may cause irritation to the skin, eyes, and respiratory system.

InChI:InChI=1/C3H6BrNO/c1-5-3(6)2-4/h2H2,1H3,(H,5,6)

Upstream product

• 598-21-0 2-Bromoacetyl bromide 
• 74-89-5 methylamine 
• 593-51-1 methylamine hydrochloride 
• 79-08-3 bromoacetic acid 
• 22118-09-8 2-bromoacetyl chloride 

Downstream Products

• 333963-31-8 2-{[6-Amino-3,5-dicyano-4-(4-hydroxyphenyl)-2-pyridinyl]sulfanyl}-N-methyl-acetamide 
• 59721-14-1 N-methylcarbamoylmethyl-p-hydroxybenzoate 
• 265983-58-2 N,N-dimethyl(2-benzyloxy-3,5-dimethyl)phenoxyacetamide 
• 1020989-19-8 2-(4-bromophenylamino)-N-methylacetamide 
• 1021003-40-6 2-((4-methylphenyl)amino)-N-methylacetamide 
• 1021087-41-1 C₉H₁₁ClN₂O 
• 1451566-31-6 C₉H₁₂N₂O₂ 

Relevant articles and documents

Structure–Activity and Structure–Toxicity Relationships of Peptoid-Based Histone Deacetylase Inhibitors with Dual-Stage Antiplasmodial Activity

Novel malaria intervention strategies are of great importance, given the development of drug resistance in malaria-endemic countries. In this regard, histone deacetylases (HDACs) have emerged as new and promising malaria drug targets. In this work, we present the design, synthesis, and biological evaluation of 20 novel HDAC inhibitors with antiplasmodial activity. Based on a previously discovered peptoid-based hit compound, we modified all regions of the peptoid scaffold by using a one-pot multicomponent pathway and submonomer routes to gain a deeper understanding of the structure–activity and structure–toxicity relationships. Most compounds displayed potent activity against asexual blood-stage P. falciparum parasites, with IC50 values in the range of 0.0052–0.25 μm and promising selectivity over mammalian cells (SIPf3D7/HepG2: 170–1483). In addition, several compounds showed encouraging sub-micromolar activity against P. berghei exo-erythrocytic forms (PbEEF). Our study led to the discovery of the hit compound N-(2-(benzylamino)-2-oxoethyl)-N-(4-(hydroxycarbamoyl)benzyl)-4-isopropylbenzamide (2 h) as a potent and parasite-specific dual-stage antiplasmodial HDAC inhibitor (IC50 Pf3D7=0.0052 μm, IC50 PbEEF=0.016 μm).

In Vitro Anti-Toxoplasma gondii Activity Evaluation of a New Series of Quinazolin-4(3H)-one Derivatives

Toxoplasmosis post serious threaten to human health, leading to severely eye and brain disease, especially for immunocompromised patients and pregnant women. The multiple side effects and long dosing period of current main treatment regiments calls for high effective and low toxicity anti-toxoplasmosis drugs. Herein, we report our efforts to synthesize a series of 2-(piperazin-1-yl)quinazolin-4(3H)-one derivatives and investigate their activity against Toxoplasma gondii tachyzoites in vitro based on cell phenotype screening. Among the 26 compounds, 8w and 8x with diaryl ether moiety at the side chain of piperazine exhibited good efficacy to inhibit T. gondii, with IC50 values of 4 μM and 3 μM, respectively. Structure-activity relationship (SAR) studies implies that hydrophobic aryl at the side chain would be preferred for improvement of activity. Molecular docking study reveals these two compounds appeared high affinity to TgCDPK1 by interaction with the hydrophobic pocket of ATP-binding cleft.

TRICYCLIC COMPOUNDS HAVING SULFINYL AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

It is intended to provide a compound that exhibits a wide antibacterial spectrum against various bacteria including gram-negative bacteria, and a pharmaceutical composition having an antibacterial activity against carbapenem-resistant bacteria.